Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York. Show more

One World Trade Center, Suite 8500, New York, NY, 10007, United States

Biotechnology

Healthcare

Start AI Chat

Market Cap

1.46B

52 Wk Range

$4.70 - $18.12

Previous Close

$0.72

Open

$0.72

Volume

1,873,938

Day Range

$0.68 - $0.72

Enterprise Value

788M

Cash

209.1M

Avg Qtr Burn

-29.57M

Insider Ownership

0.59%

Institutional Own.

41.65%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
MM120 (lysergide D-tartrate) Details Major depressive disorder	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MM120 (lysergide D-tartrate) Details Anxiety Disorders	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
MM402 (R(-)-MDMA) Details Autism spectrum disorders	Phase 2a Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.